An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study

Trial Profile

An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Docetaxel (Primary) ; PT 112 (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors SciClone Pharmaceuticals
  • Most Recent Events

    • 26 Sep 2016 According to a SciClone Pharmaceuticals media release, first patient has been treated in the phase I part of the study. The company anticipates to complete enrollment in the dose-escalation portion of the trial in early 2017.
    • 20 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top